Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of company stock tied to tax withholding. On February 23, 2026, she sold 3,419 shares of common stock in open-market transactions at a weighted average price of $14.1422 per share. The filing explains these shares were sold automatically to cover tax obligations from the vesting of restricted stock units, not at her discretion. After these transactions, she beneficially owned 141,274 shares of Amylyx common stock.
AMLX reports a proposed sale of Common stock tied to the vesting of Restricted Stock Units, totaling 10,250 shares with an anticipated action date of 02/23/2026. The filing also records that Gina Mazzariello sold 3,448 shares on 02/02/2026.
Amylyx Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with TCG Crossover hold a significant passive stake in its common stock. TCG Crossover Fund II, L.P., together with its general partner TCG Crossover GP II, LLC and Chen Yu, report beneficial ownership of 6,243,812 shares.
This position represents 5.7% of Amylyx’s outstanding common stock, based on 109,819,659 shares outstanding as of October 27, 2025. The reporting parties state they share voting and dispositive power over these shares and certify the holdings are not for the purpose of changing or influencing control of the company.
Adage Capital Management, L.P. and related individuals report beneficial ownership of 2,777,055 shares of Amylyx Pharmaceuticals common stock, representing 2.53% of the outstanding shares. The shares are held with shared voting and dispositive power and reflect ownership of 5 percent or less of the class.
The filing is an amended Schedule 13G indicating a passive investment. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx Pharmaceuticals.
FMR LLC has filed an amended Schedule 13G reporting a significant ownership stake in Amylyx Pharmaceuticals Inc. common stock. FMR and related entities beneficially own 16,468,419 shares, representing 15.0% of the outstanding common stock as of the event date.
The filing lists FMR with sole voting power over 16,417,957 shares and sole dispositive power over 16,468,419 shares. Abigail P. Johnson is reported with sole dispositive power over the same 16,468,419 shares. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock tied to equity compensation taxes. On February 2, 2026, he sold 3,557 shares of Amylyx common stock at a weighted average price of $14.6463 per share to cover tax withholding from vesting restricted stock units. After this transaction, he directly held 173,547 shares, with additional shares held in several family trusts where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock to cover taxes. On February 2, 2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.6834 per share.
The footnotes explain that these shares were required to be sold to satisfy tax withholding obligations from vested restricted stock units and were not sold at his discretion. After this tax-related sale, Cohen beneficially owned 3,363,965 shares of Amylyx common stock in direct ownership.
Amylyx Pharmaceuticals Chief Legal Officer reports automatic share sale for taxes. Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,448 shares of common stock on February 2, 2026 at a weighted average price of $14.6507 per share.
The footnotes state these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units and were not at her discretion. After this transaction, she directly holds 144,693 Amylyx common shares.
Amylyx Pharmaceuticals Co-CEO Justin B. Klee reported an automatic tax-related share sale. On 02/02/2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.685 per share to cover tax withholding tied to vesting restricted stock units.
After this transaction, Klee still beneficially owned 3,363,898 Amylyx shares directly. The filing notes the sales were required for tax withholding and were not made at his discretion, and that individual sale prices ranged from $14.510 to $14.760.
This notice reports a planned sale under Rule 144 of 15,500 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an aggregate market value of $227,593. The issuer had 3,363,965 shares outstanding at the time noted.
The securities to be sold were acquired on 02/02/2026 through the vesting of 31,667 restricted stock units. Over the prior three months, the same holder sold additional common shares, including 136,193 shares on 01/15/2026, 7,715 shares on 01/06/2026, and 1,974 shares on 01/16/2026, for disclosed gross proceeds. The signer confirms they are not aware of undisclosed material adverse information about the issuer.